Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

CELLITIS PHARMA : revenue, balance sheet and financial ratios

CELLITIS PHARMA is a French company founded 8 years ago, specialized in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques. Based in COURSEULLES-SUR-MER (14470), this company of category PME shows in 2023 a net income positive of 378 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-02

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - CELLITIS PHARMA (SIREN 833100118)
Indicator 2023 2022
Revenue N/C N/C
Net income 377 804 € 530 910 €
EBITDA N/C N/C
Net margin N/C N/C

Revenue and income statement

In 2023, CELLITIS PHARMA generates positive net income of 378 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2022-2023: 531 k€ -> 378 k€.

Net income (2023) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

377 804 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 49%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2023) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

0.0%

Financial autonomy (2023) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

49.456%

Solvency indicators evolution
CELLITIS PHARMA

Sector positioning

Debt ratio
0.0 2023
2022
2023
Q1: 0.0
Med: 5.57
Q3: 50.77
Excellent

In 2023, the debt ratio of CELLITIS PHARMA (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.

Financial autonomy
49.46% 2023
2022
2023
Q1: 13.47%
Med: 38.42%
Q3: 58.45%
Good -12 pts over 2 years

In 2023, the financial autonomy of CELLITIS PHARMA (49.5%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 197.72. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2023) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

197.719

Liquidity indicators evolution
CELLITIS PHARMA

Sector positioning

Liquidity ratio
197.72 2023
2022
2023
Q1: 133.58
Med: 205.53
Q3: 329.15
Average -28 pts over 2 years

In 2023, the liquidity ratio of CELLITIS PHARMA (197.72) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Positioning of CELLITIS PHARMA in its sector

Comparison with sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Valuation estimate

Based on 124 transactions of similar company sales (all years), the value of CELLITIS PHARMA is estimated at 310 371 € (range 118 129€ - 1 133 438€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2023
124 transactions
118k€ 310k€ 1133k€
310 371 € Range: 118 129€ - 1 133 438€
NAF 5 all-time

Valuation method used

Net Income Multiple
377 804 € × 0.8x = 310 372 €
Range: 118 130€ - 1 133 439€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 124 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de gros (commerce interentreprises) de produits pharmaceutiques)

Compare CELLITIS PHARMA with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Frequently asked questions about CELLITIS PHARMA

What is the revenue of CELLITIS PHARMA ?

The revenue of CELLITIS PHARMA is not publicly disclosed (confidential accounts filed with INPI).

Is CELLITIS PHARMA profitable?

Yes, CELLITIS PHARMA generated a net profit of 378 k€ in 2023.

Where is the headquarters of CELLITIS PHARMA ?

The headquarters of CELLITIS PHARMA is located in COURSEULLES-SUR-MER (14470), in the department Calvados.

Where to find the tax return of CELLITIS PHARMA ?

The tax return of CELLITIS PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does CELLITIS PHARMA operate?

CELLITIS PHARMA operates in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques (NAF code 46.46Z). See the 'Sector positioning' section above to compare the company with its competitors.